| Budget Amount *help |
¥5,901,294 (Direct Cost: ¥4,931,765、Indirect Cost: ¥969,529)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2008: ¥2,121,294 (Direct Cost: ¥1,631,765、Indirect Cost: ¥489,529)
Fiscal Year 2007: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Research Abstract |
(1) Secondary progressive multiple sclerosis (SPMS) had a normal function of the regulatory T cells, therefore SPMS had a small number of clonally expanded pathogenic T cells. Neuromyelitis optica expressed results exactly the opposite of SPMS. Japanese multiple sclerosis patients must choice the appropriate therapy according to their classified type.
(2) Early interferon therapy for the Japanese multiple sclerosis patients suppresses the number of relapse and the MRI lesions. Moreover, it effect to sustain the quality of life for the patients.
(3) Because the secondary progressive neuromyelitis optica patients reveal the inflammation and demyelination, they must not be treated with interferon.
|
